Therapeutic action of the evolocumab monoclonal antibody against PCSK9 proteins in LDL cholesterol modulation: systematic review
Introduction: The hypercholesterolemia can lead to conditions such as acute myocardial infarction (AMI). However, cholesterol elevation is not always caused by poor diet habits and lifestyle; groups such as familial hypercholesterolemia (HF) have serum values increased by genetic alterations, and tr...
| Autores: | , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2017 |
| País: | Brasil |
| Institución: | Universidade Municipal de São Caetano do Sul (USCS) |
| Repositorio: | Revista de Atenção à Saúde |
| Idioma: | portugués |
| OAI Identifier: | oai:ojs2.seer.uscs.edu.br:article/4439 |
| Acceso en línea: | http://seer.uscs.edu.br/index.php/revista_ciencias_saude/article/view/4439 |
| Access Level: | acceso abierto |
| Palabra clave: | Hiperlipoproteinemia tipo II Lipoproteínas LDL Infarto do miocárdio PCSK9 Hyperlipoproteinemia type II LDL lipoproteins Myocardial infarction |
| Sumario: | Introduction: The hypercholesterolemia can lead to conditions such as acute myocardial infarction (AMI). However, cholesterol elevation is not always caused by poor diet habits and lifestyle; groups such as familial hypercholesterolemia (HF) have serum values increased by genetic alterations, and traditional dyslipidemic medications are not effective enough for these peoples. Objective: To compile and discuss the results obtained by the current literature that focuses on the evolocumab monoclonal antibody to decrease PCSK9 levels. Materials and methods: Systematic review of the results of tests done with humans over 19 years of age, published in the last 5 years in the English language, using the PubMed database. Results: 135 articles were found, and nine studies were selected by exclusion criteria. Discussion: Results demonstrated that the pharmacological power of the evolocumab antibody has a remarkable value compared to the usual therapies and placebo for patients who did not show great response to current therapies. Conclusion: This is a very recent study, which requires further research to show possible adverse reactions and interactions with other drugs. However, so far it has demonstrated a great advantage for future treatments because it occupies a place not previously filled by traditional pharmacology. |
|---|